Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 2
Submit an article Journal homepage
227
Views
13
CrossRef citations to date
0
Altmetric
Review

Review of studies reporting actual prices for medicines

Nika MardetkoFaculty of pharmacy, University of Ljubljana, Ljubljana, SloveniaView further author information
,
Mitja KosFaculty of pharmacy, University of Ljubljana, Ljubljana, SloveniaView further author information
&
Sabine VoglerWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian Public Health Institute), Vienna, AustriaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4853-4397View further author information
ORCID Icon
Pages 159-179 | Received 17 Apr 2018, Accepted 21 Nov 2018, Published online: 07 Dec 2018

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Fei Yuan, Shrikant I. Bangdiwala, Wesley Tong & Andre Lamy. (2023) The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices. Expert Review of Pharmacoeconomics & Outcomes Research 23:1, pages 69-78.
Read now

Articles from other publishers (12)

Hans Kjellberg, Ebba Sjögren & Linus Johansson Krafve. (2023) The functions of known to be inaccurate prices in markets: A cross-country comparison of pharmaceutical list pricing. Journal of Business Research 167, pages 114193.
Crossref
Nuha Khalfay, Eric Lo, Tamara Grisales & A. Lenore Ackerman. (2023) An Analysis of Stated Insurance Coverage and Estimated Patient-Incurred Costs of Treatments for Lower Urinary Tract Symptoms. Urogynecology 29:2, pages 287-294.
Crossref
Eirik Joakim Tranvåg, Øystein Ariansen Haaland, Bjarne Robberstad & Ole Frithjof Norheim. (2022) Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions. JAMA Network Open 5:6, pages e2219503.
Crossref
Suaad Almajed, Nora Alotaibi, Sana Zulfiqar, Zahraa Dhuhaibawi, Niall O’Rourke, Richard Gaule, Caoimhe Byrne, Aaron M. Barry, Dylan Keeley & James F. O’Mahony. (2021) Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability. The European Journal of Health Economics 23:3, pages 375-431.
Crossref
Dominik J. Wettstein & Stefan Boes. (2022) How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence. Health Policy 126:2, pages 112-121.
Crossref
Nora Franzen, Andreas Ziegler, Giorgia Romagnoli, Valesca P. Retèl, Theo J.S. Offerman & Wim H. van Harten. (2022) Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations. Cancer Research Communications 2:1, pages 49-57.
Crossref
Pierluigi Russo, Angelica Carletto, Gergely Németh & Claudia Habl. (2021) Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy 125:9, pages 1140-1145.
Crossref
Dominik J. Wettstein & Stefan Boes. (2021) Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept. BMC Health Services Research 21:1.
Crossref
Dominik J. Wettstein & Stefan Boes. (2020) The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment. Health Economics Review 10:1.
Crossref
Sabine Vogler, Peter Schneider & Lena Lepuschütz. (2020) Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Sabine Vogler. 2020. Global Pharmaceutical Policy. Global Pharmaceutical Policy 99 137 .
Jonas Lohmüller, Melanie Schröder & Carsten Telschow. 2019. Arzneiverordnungs-Report 2019. Arzneiverordnungs-Report 2019 249 299 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.